JKJean Kim

Jean Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean Kim has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Radiation Vasculopathy of the Coronary Arteries: State-of-the Art Review

    by Jeffrey Xia, Jean Kim, Abhishek Sharma, Benjamin Yang, Prasanna G. Alluri, Katelyn Atkins, Eric D. Miller, Terence M. Williams, Daniel Addison, Amit Arbune, et al.

    Radiation-associated coronary artery disease (RACAD) is a distinct form of coronary artery disease with several specific biological and clinical aspects as well as key knowledge gaps. RACAD is prevalent in patients with cardiac exposure to radiotherapy. As radiotherapy is integral to the effective treatment of many thoracic malignancies, improved long-term survivorship is coupled with increased risk for RACAD. Ionizing radiation induces free radical generation and activation of proinflammatory cascades, leading to endothelial dysfunction and accelerated atherosclerosis. Risks for RACAD are determined both by radiotherapy, including the radiation dose and the proximity of coronary arteries to the radiotherapy field, and by patient-specific factors, such as younger age, higher baseline cardiovascular risk, and concurrent cardiotoxic systemic therapies. Importantly, radiotherapy delivery is highly individualized on the basis of tumor location and treatment strategy, resulting in heterogeneous coronary exposure to radiation and patient-to-patient variability. Clinical presentation may occur early, within 1 to 2 years, especially in patients with higher cardiac radiation doses (eg, lung or esophageal cancer), or after a latency period of 5 to 20 years with lower cardiac dose radiation exposure (eg, left-sided breast cancer). Patients generally present with symptoms similar to conventional coronary artery disease. However, RACAD symptoms may be underrecognized in cancer survivors due to overlapping treatment-related fatigue, pulmonary disease, or competing oncologic symptoms. Diagnosis and management generally follow standard coronary artery disease guidelines while incorporating cancer-specific considerations, such as planned oncologic surgeries, bleeding risk, postradiotherapy complications such as atretic internal mammary arteries, and cardiotoxic effects of systemic cancer therapies. Primary prevention of RACAD is critical, emphasizing advances in precision radiotherapy, including delivery techniques with improved coronary dosimetry, and cardiac shielding. Key knowledge gaps include understanding long-term outcomes with contemporary 3-dimensional conformal radiotherapy techniques, validated cancer-specific risk prediction models on the basis of coronary dosimetry, optimal surveillance protocols, targeted molecular pharmacotherapies, and risk analysis of percutaneous versus surgical management of RACAD. Prospective studies are needed to develop cancer- and dosimetry-specific risk calculators, validating cardioprotective interventions, and improving multidisciplinary cardio-oncology collaboration to optimize early detection of RACAD and timely intervention in the growing population of cancer survivors.

  • Open Access

    Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis

    by Jean Kim, Kyle Miyazaki, Parthav Shah, Landon Kozai, Jakrin Kewcharoen

    Since the onset of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, various potential targeted therapies for SARS-CoV-2 infection have been proposed. The protective effects of mineralocorticoid receptor antagonists (MRA) against tissue fibrosis, pulmonary and systemic vasoconstriction, and inflammation have been implicated in potentially attenuating the severity of SARS-CoV-2 infection by inhibiting the deleterious effects of aldosterone. Furthermore, spironolactone, a type of MRA, has been suggested to have a beneficial effect on SARS-CoV-2 outcomes through its dual action as an MRA and antiandrogen, resulting in reduced transmembrane protease receptor serine type 2 (TMPRSS2)-related viral entry to host cells. In this study, we sought to investigate the association between MRA antagonist therapy and mortality in SARS-CoV-2 patients via systematic review and meta-analysis. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE and EMBASE databases were searched for studies that reported the incidence of mortality in patients on MRA with SARS-CoV-2 infection. Pooled odds ratio (OR) and 95% confidence interval (CI) of the outcome were obtained using the random-effects model. Five studies with a total of 1,388,178 subjects (80,903 subjects receiving MRA therapy) met the inclusion criteria. We included studies with all types of MRA therapy including spironolactone and canrenone and found no association between MRA therapy and mortality in SARS-CoV-2 infection (OR = 0.387, 95% CI: 0.134–1.117, p = 0.079).


  • Open Access

    Inappropriate Telemetry Use Is Increased during the COVID-19 Era

    by Jean Kim, Kyle Miyazaki, Yoshito Nishimura, Ryan Honda

    Due to the unprecedented COVID-19 pandemic, there may be overuse of telemetry monitoring compared to the pre-pandemic period. We compared the frequency of inappropriate telemetry use in the pre-COVID-19 period (1 November 2019 to 28 February 2020) versus the peri-COVID-19 period (1 March 2020 to 30 June 2020) at a major academic hospital in Honolulu, Hawaii, by a retrospective chart review to assess for the appropriateness of the telemetry orders during this period, based on the 2017 American College of Cardiology/American Heart Association guidelines. Compared to the pre-COVID-19 period, there was a significant increase in inappropriate telemetry use during the peri-COVID-19 period (X2 (1, N = 11,727) = 6.59, p = 0.0103). However, there was no increase in the proportions of respiratory failure (4.0%) or pneumonia (2.7%) during the peri-COVID-19 period. The increase in inappropriate telemetry use may be related to the uncertainty in clinical care and decision making amid the pandemic of the new virus. Appropriate utilization of telemetry monitoring is increasingly important during the pandemic due to the limited availability of resources. Further investigation is needed to clarify the relationship between the pandemic and trends in telemetry ordering.


  • Open Access

    Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis

    by Jean Kim, Yoshito Nishimura, Jakrin Kewcharoen, James Yess

    There is insufficient evidence about the cardioprotective effects of statins against chemotherapy-induced cardiomyopathy. The MEDLINE and EMBASE databases were searched from inception to March 2021 for studies that reported the mean left ventricular ejection fraction (LVEF) before and after chemotherapy and the incidence of chemotherapy-induced cardiotoxicity in patients who received concurrent statin therapy and those who received chemotherapy alone. A random effects meta-analysis was performed to obtain the pooled weighted mean difference (WMD) and the 95% confidence interval (CI) for the mean final LVEF and the mean LVEF change, and the pooled odds ratio (OR) and the 95% CI of the incidence of chemotherapy-induced cardiomyopathy. Seven studies with 3042 patients were included in this meta-analysis (statin group: 1382 patients received concurrent statin with chemotherapy; control group: 1660 patients received chemotherapy alone). Patients in the control group had a more significant decline in LVEF (WMD = −6.08%, 95% CI: −8.55 to −3.61, p < 0.001) compared to those in the statin group. Additionally, the statin group had a significantly lower incidence of chemotherapy-induced cardiomyopathy compared to the control group (OR = 0.41, 95% CI = 0.28–0.60, p < 0.001). Consequently, our study showed a significant reduction in the incidence of chemotherapy-induced cardiomyopathy and the degree of LVEF decline in patients in the statin group compared to those in the control group.


  • Open Access

    Association between Subclinical Hypothyroidism and Incident Hypertension in Women: A Systematic Review and Meta-Analysis

    by Jean Kim, Narut Prasitlumkum, Sandeep Randhawa, Dipanjan Banerjee

    Subclinical hypothyroidism (SCH) has been found to be associated with an increased risk of cardiovascular diseases. However, there is no clear consensus on the relationship between SCH and hypertension (HTN). We sought to investigate the association between SCH and incident HTN in women. MEDLINE and EMBASE databases were searched for studies that reported the incidence of HTN in females with SCH versus without SCH. Pooled odds ratio (OR) and 95% confidence interval (CI) of the outcome were obtained using a random-effects model. Studies were also divided into the middle-aged (mean age < 65) and the older (mean age ≥ 65) subgroups, and a subgroup analysis was performed to examine the potential age-effect on the association between SCH and HTN. Nine studies with a total of 21,972 subjects met the inclusion criteria. SCH was found to be positively associated with HTN (OR = 1.32, 95% CI = 1.02–1.71). Such association varied depending on the age of women. In the middle-aged subgroup, SCH was more positively associated with HTN (OR = 1.64, 95% CI = 1.18–2.27), while there was no significant association in the older subgroup (OR = 0.97, 95% CI = 0.80–1.16). Our study showed that the middle-aged females with SCH had an increased risk of HTN, while there was no significant association in the older females with SCH.


  • Uncommon obstacle: management of end-stage heart failure in thrombocytopenia with absent radii (TAR) syndrome

    by Jean Kim, Jakrin Kewcharoen, Corey J Lum, Steven S Azuma

    Thrombocytopenia with absent radii (TAR) syndrome is a rare genetic condition causing absent radial bones and thrombocytopenia. Management is generally supportive although there may be a role for platelet-stimulating agents such as romiplostim. In this case, we highlight the obstacles in managing end-stage heart failure in a patient with TAR syndrome.


  • Open Access

    Infective Endocarditis Involving Mitral and Aortic Valves With Interatrial Septal Abscess

    by Jean Kim, James Ha, Christina Park, Eric Y. Chung

    Infectious endocarditis (IE) is an infection of the endocardial surface and frequently refers to the infection of one or more heart valves. The clinical manifestations of IE are highly variable, with fever being the most common symptom, along with other nonspecific symptoms such as chills, anorexia, malaise, and myalgias. IE is associated with various systemic complications including septic emboli, cardiac complications such as valvular vegetations and intracardiac abscess, neurologic complications, and systemic immune reactions. In this case report, we present a patient with an IE that involved both mitral and aortic valves as well as a unique pathology with an interatrial septal abscess.


  • Open Access

    Recurrent Gastrointestinal Bleeding in a Patient With Severe Aortic Valve Stenosis: A Diagnosis of Heyde’s Syndrome

    by Adham E Obeidat, Jean Kim

    Heyde’s syndrome is defined as the coexistence of aortic valve stenosis (AS) and recurrent gastrointestinal (GI) bleeding from intestinal angiodysplasia (IA). Despite the fact that Heyde’s syndrome was first described decades ago, the association between AS and IA remains frequently unidentified, and thus, a high clinical suspicion is needed for its diagnosis. Here we present a case of a 60-year-old man with a history of severe AS, who presented with recurrent GI bleeding and was found to have multiple intestinal angioectasias on endoscopy.


  • Open Access

    Neonatal Enterovirus Infection: Case Series of Clinical Sepsis and Positive Cerebrospinal Fluid Polymerase Chain Reaction Test with Myocarditis and Cerebral White Matter Injury Complications

    by Julie B. Lindower, Heather L. Bartlett, Dianne L. Atkins, Jean O. Kim, Jonathan M. Klein, Bradley A. Ford, Frank H. Morriss

    Objective We describe five neonates with enteroviral (EV) infection to demonstrate central nervous system (CNS) and cardiac complications and report successful treatment of myocarditis with immunoglobulin intravenous (IVIG) in two. Study Design Case series identified during three enteroviral seasons in one neonatal intensive care unit (NICU) by cerebral spinal fluid (CSF) reverse transcriptase polymerase chain reaction (PCR) testing for EV in neonates suspected to have sepsis, but with sterile bacterial cultures. Results Cases were identified in each of three sequential years in a NICU with 800 to 900 admissions/year. Two cases were likely acquired perinatally; all were symptomatic with lethargy and poor feeding by age 5 to 10 days. All had signs of sepsis and/or meningitis; one progressed to periventricular leukomalacia and encephalomalacia. Two recovered from myocarditis after treatment that included IVIG 3 to 5 g/kg. Conclusion Neonates who appear septic without bacterial etiology may have EV CNS infections that can be diagnosed rapidly by CSF PCR testing. Cases may be underdiagnosed in the early neonatal period if specific testing is not performed. Neonates with EV infection should be investigated for evidence of periventricular leukomalacia, screened for myocarditis, and considered for IVIG treatment.